A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis.

Trial Profile

A Multi-centre, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Identify the Optimal Dose of PURETHAL Mites SCIT in Patients With House Dust Mites-induced Persistent Allergic Rhinitis/Rhinoconjunctivitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2014

At a glance

  • Drugs House dust mite allergy immunotherapy subcutaneous HAL Allergy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors HAL Allergy
  • Most Recent Events

    • 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Mar 2012 This trial is expected to be completed in the beginning of 2013, according to a HAL Allergy media release.
    • 20 Mar 2012 Status changed from recruiting to active, no longer recruiting, according to a HAL Allergy media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top